A wide portfolio of Life Science startups
Whilst the Norwegian life science scene is increasingly attracting international attention, interest in funding of the early-phase of the prospect still comes mainly from homegrown investors, with international investors looking to invest in more mature cases. Sarsia Seed holds unique combination of deep technical knowledge, market understanding and an extensive network. Using a strategy of optimal timing, Sarsia Seed has on multiple occasions, been successful in creating greater potential Exit opportunities.
Substantial improvements in health outcomes of chronic and infectious diseases have created an increase in age and life-style related diseases such as metabolic diseases and cancer. The predicted incidence of cancer is forecasted to increase substantially over the next few decades across all regions of the world. The past ten years have also seen a dramatic increase in the prevalence of lifestyle-influenced or behavior-related chronic diseases, such as obesity and diabetes. The International Diabetes Federation (IDF) estimated that the number of people with diabetes globally was some 415 million, and that, in 2015, five million people died from causes associated with having diabetes (one death every six seconds), more than all the deaths from malaria, tuberculosis, and HIV combined. The global cost of treating diabetes is estimated at over $670 billion dollars a year.
The Nordic region is one with world class science and expertise particularly in the areas of cancer, immunology, neurology, infectious diseases, metabolic diseases and personlaised medicine. International focus on Norway has increased ever since pharma giant Bayer AG’s takeover of Norwegian biotech Algetain 2014 in a deal worth NOK 17.6 billion. Over the past decade, an exceedingly strong life science environment has been developing in Norway, in particular in the area around Oslo’s university hospital, Radiumhospitalet, and the biotech hub Oslo Cancer Cluster (OCC). The OCC has been rated as one of the top oncology/immun-oncology clusters in Europe and is among the best centres for cancer research. In going beyond cancer, the 2014 Nobel Prize in medicine or physiology was given to a Norwegian research couple for discoveries relating to the central nervous system.
However, the volume of financing currently afforded potential prospects falls far short of the potential volume which could be realized due to the lack of regional/local specialist VC operating in the Norwegian LS sector. This results in a high deal flow of high quality prospects forming an opportunity for attractive investments for a regional specialist early-stage LS VC such as Sarsia.